

October 28, 2026

Company Name: Veritas In Silico Inc.

Representative: Shingo NAKAMURA,

Representative Director and CEO

Listed on: TSE Growth

Stock Ticker Code: 130A

Contact : Tsuneo GODA,

Executive Officer, General Manager,

Corporate Planning Division


Email: ir@veritasinsilico.com

Notice of Trademark Registration Completed for Drug Delivery System “Perfusio[®]”

Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; Representative Director and CEO: Shingo NAKAMURA, hereinafter referred to as "the Company") hereby announces that trademark registration has been completed for its proprietary drug delivery system (DDS), “Perfusio[®].”

● Outline of the Trademark Registration

- **Trademark:** Perfusio
- **Trademark Registration:** No. 70800185
- **Trademark Owner:** Veritas In Silico Inc.



(Figure) Conceptual illustration of Perfusio[®]

● Outline of “Perfusio®”

“Perfusio®” is a DDS designed to temporarily isolate a target organ from systemic circulation by positioning catheters on both the arterial and venous sides of the organ and occluding the relevant blood vessels. In this isolated state, a pharmaceutical product can be administered through one catheter and recovered through the other, with the aim of delivering the pharmaceutical directly to the target organ while limiting systemic exposure.

A key feature of “Perfusio®” is its potential applicability to a broad range of pharmaceuticals, including nucleic acid therapeutics, small-molecule drugs and antibody therapeutics, without necessarily requiring chemical modification of the pharmaceutical product for DDS purposes.

● Commercialization Strategy for Perfusio®

The Company is working toward the commercialization of “Perfusio®” as a general-purpose medical device, with the aim of commencing manufacturing and marketing in fiscal year 2027. The Company is currently making preparations to obtain the necessary regulatory approval and exploring opportunities for collaboration with catheter-related companies and potential partnerships with pharmaceutical companies.

The trademark registration represents an important step in protecting the “Perfusio®” brand and advancing its commercialization.

END

For Further Information, Contact:

- Veritas In Silico Website Inquiry Form : <https://www.veritasinsilico.com/en/contact/>